Thetis Pharmaceuticals

November 25, 2019November 25, 2019

Thetis Receives Funds From Crohn’s & Colitis Foundation to Further Develop TP-317 for IBD

News

The Crohn’s & Colitis Foundation is providing funding support to Thetis Pharmaceuticals for the continuing development of the novel oral therapy TP-317 for the treatment of inflammatory bowel disease (IBD). ... Read more

May 30, 2018May 30, 2018

Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis

News

Thetis Pharmaceuticals recently received a $1.9 million fast-track Small Business Innovation Research grant from the National Institutes of Health (NIH) to help advance the development of TP-252, an investigational oral therapy for ulcerative ... Read more